Amatuximab

DRUG2 trials

Sponsors

Morphotek

Conditions

MesotheliomaMesothelioma, MalignantNon-small Cell Lung CancerOvarian CancerPancreatic Cancer

Phase 1

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

CompletedNCT01521325

MorphotekMesothelioma, Non-small Cell Lung Cancer, Ovarian Cancer +1

Start: 2011-09-30End: 2013-03-31Updated: 2016-09-30

Phase 2

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)

TerminatedNCT02357147

MorphotekMesothelioma, Malignant

Start: 2015-11-03End: 2018-11-30Updated: 2020-03-17